Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen Earnings Beat Expectations; Company Pushing Payers On Repatha

Executive Summary

Amgen Inc.'s first quarter revenue and earnings beat consensus estimates without a meaningful contribution from sales of the cholesterol-reducing biologic Repatha (evolocumab), but the company is pushing back against payers that are denying reimbursement to appropriate patients.


Related Content

1Q Earnings Preview: What To Expect From US, EU Big Hitters
Alder Readies To Take On Teva, Others In Migraine
Amgen/Apotex Appeals Arguments Aimed At April
1st U.S. Biosimilar Arrives: Zarxio Launches; Legal Saga Ongoing
Repatha OK'd; Payers Eye PCSK9 Rebate/Discount War
Amgen's Blincyto on path to broader ALL indication
Teva, Lilly and Amgen join battle for new $8bn migraine prevention market
Vectibix extends OS in colorectal cancer
Kyprolis ENDEAVOR data signal a changing of the guard for multiple myeloma treatment
Amgen gains early US win for BiTE antibody Blincyto


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst